2027 Antibiotic Reference Guide

Generic Names • Trade Names • AST Abbreviations • Routes • Market Status



β-LACTAM ANTIBIOTICS

Generic Name	Trade Name(s)	Abbreviations	Spectrum	Route(s)	Status
Penicillins					
Amoxicillin	Amoxil, Dispermox, Larotid	AMX, Amx, AMOX, AC, AML, A	G+ / G-	PO	●
Ampicillin	Pfizerpen-A	AM, Am, AMP, AP	G+ / G-	PO/IM/IV	●
Oxacillin	Bactocill	Ox, OX, OXS, OXA	G+	PO/IV	●
Penicillin	Permapen, Pfizerpen	P, PEN, PV, PG	G+	PO/IM/IV	●
Piperacillin	Pipracil	Pi, PI, PIP, PP	G+ / G-	IM/IV	▲
Ticarcillin	Ticar	Ti, TI, TIC, TC	G+ / G-	IM/IV	▲
Amoxicillin-clavulanate	Augmentin	AMC, Amc, A/C, AUG, Aug, XL, AML	G+ / G-	PO	●
Ampicillin-sulbactam	Unasyn	SAM, A/S, AMS, AB	G+ / G-	IV	●
Piperacillin-tazobactam	Zosyn	P/T, PTc, PTZ, TZP	G+ / G-	IV	●
Ticarcillin-clavulanate	Timentin	TIM, Tim, T/C, TCC, TLc, TTC	G+ / G-	IM/IV	▲
Cephalosporins					
Cefaclor	Cefaclor	CCL, CEC, Cfr, FAC, CF	G+ / G-	PO	●
Cefadroxil	Duricef	CFR, FAD, CDX	G+ / G-	PO	●
Cefazolin	Ancef	Cfz, CZ, CFZ, FAZ, KZ, CZN	G+ / G-	IM/IV	●
Cefdinir	Omnicef	Cdn, CDR, DIN, CD, CFD	G+ / G-	PO	●
Cefditoren	Spectracef	CDN	G+ / G-	PO	▲
Cefepime	Maxipime	FEP, Cpe, PM, CPM	G+ / G-	IM/IV	●
Cefixime	Suprax	Cfe, DCFM, FIX, IX	G+ / G-	PO	●
Cefoperazone	Cefobid	Cfp, CFP, CPZ, PER, FOP, CP	G-	IM/IV	▲
Cefotaxime	Claforan	CTX, TAX, Cft, FOT, CT	G+ / G-	IM/IV	■
Cefotetan	Cefotan	Ctn, CTN, CTT, CTE, TANS, CN	G+ / G-	IM/IV	●
Cefoxitin	Mefoxin	Cfx, FOX, CX, FX	G+ / G-	IM/IV	●
Cefpodoxime	Vantin	Cpd, CPD, POD, PX	G+ / G-	PO	●
Cefprozil	Cefzil	CPZ, CPR, FP	G+ / G-	PO	●
Ceftaroline	Teflaro	CPT, Cpt, CTR	G+ / G-	IV	●
Ceftazidime	Fortaz, Tazicef, Tazidime	CAZ, Caz, TAZ, TZ	G-	IM/IV	●
Ceftazidime-avibactam	Avycaz	CZA	G-	IV	●
Ceftibuten	Cedax	CTB, TIB, CB	G+ / G-	PO	▲
Ceftizoxime	Cefizox	Cz, ZOX, CZX, CZ, CTZ, TIZ	G-	IM/IV	▲
Ceftobiprole	Zevtera	BPR	G+	IV	●
Ceftolozane-tazobactam	Zerbaxa	CT, C/T, CXT, CLT	G+ / G-	IV	●
Ceftriaxone	Rocephin	CRO, CTR, FRX, Cax, AXO, TX	G+ / G-	IM/IV	●
Cefuroxime (oral/parenteral)	Ceftin (oral), Zinacef (IM/IV)	CXM, CFX, ROX, Crm, FUR, XM	G-	PO/IM/IV	●
Cephalexin	Keflex, Panixine	CN, LEX, CFL	G+ / G-	PO	●
Cephalothin	Keflin	Cf, CF, CR, CL, CEP, CE, KF	G+ / G-	IM/IV	▲
Loracarbef	Lorabid	Lor, LOR, LO	G+ / G-	PO	▲
Penems					
Doripenem	Doribax	DOR, Dor	G-	IV	▲
Ertapenem	Invanz	ETP, Etp	G+ / G-	IM/IV	●
Faropenem	Farom	FAR, FARO	G+ / G-	PO	◆
Imipenem	Primaxin	IPM, IMI, Imp, IP	G+ / G-	IV	●
Meropenem	Merrem	MEM, Mer, MERO, MRP, MP	G+ / G-	IV	●
Imipenem-relebactam	Recarbrio	IMR, IPR, I/R	G+ / G-	IV	◆
Meropenem-vaborbactam	Vabomere	MEV	G-	IV	●
Tebipenem pivoxil	Utebzi	TBP	G-	PO	●
Monobactams					
Aztreonam	Azactam	ATM, AZT, Azt, AT, AZM	G-	IM/IV/INH	●
Aztreonam-avibactam	Emblaveo	AZA	G-	IV	●
Other β-Lactams					
Cefiderocol	Fetroja	FDC	G-	IV	●
Cefepime-enmetazobactam	EXBLIFEP	FPE	G-	IV	●
Cefepime-taniborbactam	-	FTB	G-	IV	■
Sulbactam-durlobactam	Xacduro	SUD, SUL	G-	IV	●
Sulopenem-etzadroxil/probenecid	Orlynvah	SE/probenecid	G+ / G-	PO	●

NON β-LACTAM ANTIBIOTICS

Generic Name	Trade Name(s)	Abbreviations	Spectrum	Route(s)	Status
Aminoglycosides					
Amikacin	Amikin	AN, AK, Ak, AMI, AMK, AKN	G-	IM/IV	●
Gentamicin	Garamycin, Genoptic	GM, Gm, CN, GEN	G+ / G-	IM/IV	●
Kanamycin	Kantrex	K, KAN, HLK, KM	G+ / G-	IM/IV	▲
Netilmicin	Netromycin	NET, Nt, NC	G-	IM/IV	◆
Tobramycin	Tobi, Aktob, Tobrex	TM, NN, TO, To, TOB, TN	G-	IM/IV/INH	●
Plazomycin	Zemdri	PLZ	G-	IV	●
Streptomycin	Streptomycin Sulfate	S, STR, SM	G+	IM/IV	●
Quinolones					
Ciprofloxacin	Cipro, Ciloxan	CIP, Cp, Cl	G+ / G-	PO/IV	●
Delafloxacin	Baxdela	DFX	G+ / G-	PO/IV	●
Levofloxacin	Levaquin	LVX, Lvx, LEV, LEVO, LE	G+ / G-	PO/IV	●
Lomefloxacin	Maxaquin	Lmf, LOM	G-	PO	▲
Moxifloxacin	Avelox, Vigamox	MXF, Mxf, MX	G+ / G-	PO/IV	●
Nalidixic Acid	NegGram	NA, NAL	G+ / G-	PO	▲
Ofloxacin	Floxin, Ocuflox (ophthalmic)	Ofl, OFL, OFX, OF	G+ / G-	PO/OTIC/ OPHTH	●
Macrolides / Ketolides					
Azithromycin	Zithromax	AZM, Azi, AZI, AZ, ATH	G+ / G-	PO, IV	●
Clarithromycin	Biaxin	CLR, CLM, CLA, Cla, CH	G+ / G-	PO	●
Erythromycin	Eryc, Eryped, Erythrocin, E-Glades, E-Mycin, E.E.S., Ery-Tab, Eryc, Eryderm, Erygel, Eryped, Erythra-derm, Eryzole	E, ERY, EM	G+ / G-	PO, IV	▲
Telithromycin	Ketek	TEL	G+	PO	▲
Tetracyclines / Glycylcyclines					
Doxycycline	Vibramycin	DO, DOX, DC, DOXY, D, DX Dox, DXT	G+ / G-	PO/IV	●
Eravacycline	Xerava	ERV	G+ / G-	IV	●
Gepotidacin	Blujepa	GEP	G+ / G-	PO	●
Lefamulin	Xenleta	LMU	G+	PO/IV	●
Minocycline	Minocin, Arestin, Solodyn	MI, MIN, Min, MN, MNO, MC, MH	G+ / G-	PO/IV	●
Omadacycline	Nuzyra	OMC	G+ / G-	PO/IV	●
Tetracycline	Tetrex	TE, Te, TET, TC	G+ / G-	PO/IV	●
Tigecycline	Tygacil	TGC, Tgc	G+ / G-	IV	●









Status Legend

●	U.S. Marketed
●	Generic Only (no current major U.S. trade name)
▲	Discontinued / Historical (refer to notes)
◆	Non-U.S. (included for international or AST relevance)
■	Investigational / Not FDA Approved

Spectrum Key

G+	=	Primarily Gram-positive
G-	=	Primarily Gram-negative
G+/G-	=	Broad Spectrum
ANAES	=	Anaerobes

ADDITIONAL ANTIBIOTIC CLASSES

Generic Name	Trade Name(s)	Abbreviations	Spectrum	Route(s)	Status
Glycopeptides					
Dalbavancin	Dalvance	DAL	G+	IV	●
Oritavancin	Orbactiv	ORI	G+	IV	●
Teicoplanin	Targocid	Tei, TEI, TEC, TPN, TP, TPL	G+	IM/IV	◆
Telavancin	Vibativ	TLV, TLA	G+	IV	●
Vancomycin	Vancocin, Vancomycin Hydrochloride	Va, VA, VAN	G+	PO/IV	●
Lipopeptides					
Daptomycin	Cubicin	Dap	G+	IV	●
Oxazolidinones					
Contezolid	Youxitai	CZD	G+	PO/IV	◆
Linezolid	Zyvox	LNZ, LZ, LZD, Lzd	G+	PO/IV	●
Tedizolid	Sivextro	TZD	G+	PO/IV	●
Lincosamides					
Clindamycin	Cleocin, Clinda-derm, Clindagel, Clindesse, Clindets, Evoclin	CC, CM, CD, Cd, CLI, DA	G+ / G-	PO/IM/IV	●
Polymyxins					
Colistin (colistimethate)	Coly-Mycin	CL, CS, CT, Cl, CO, COL	G-	IV	●
Polymyxin B	Poly-RX	PB	G-	IV	●
Nitroimidazoles					
Metronidazole	Flagyl, MetroGel, Metrocream, Metrolotion	MTZ	ANAES	PO/IV	●
Rifamycins					
Rifampin	Rifadin	Rif, RIF, RA, RI, RD	G+	PO/IV	●
Rifampin+Isoniazid	Rifamate	RIF	G+	PO	●
Other Agents					
Chloramphenicol	Chloromycetin	C, CHL, CL	G+ / G-	PO/IV	●
Fosfomycin	Monurol	FOS	G+ / G-	PO	●
Fosfomycin Disodium	Contepo	FOS (IV)	G-	IV	●
Fusidic Acid	Fucidin	FA, FUS	G+	PO	◆
Mupirocin	Bactroban, Centany	MUP, MOP, MU	G+	Topical	●
Nitrofurantoin	Furadantin, Macrobid, Macrodantin	Fd, FD, F/M, FT, NIT, NI, F	G-	PO	●
Quinupristin-dalfopristin	Synercid	Syn, SYN, QDA, RP	G+	IV	▲
Spectinomycin	Trobicin	SPT, SPE, SC	G-	IM/IV	▲
Trimethoprim	Primsol, Proloprim	T, TMP, TR, W	G+ / G-	PO	●
Trimethoprim-sulfamethoxazole	Bactrim, Septra, Sulfatrim	T/S, SXT, SxT, TS, COT	G+ / G-	PO	●
Zoliflodacin	Nuzolvence	ZFD	G-	PO	●

References

U.S. Food and Drug Administration
"Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)." FDA, U.S. Department of Health and Human Services.

U.S. Food and Drug Administration
"Additions/Deletions for Prescription and OTC Drug Product Lists." FDA, U.S. Department of Health and Human Services.

U.S. Food and Drug Administration
"Drug Shortages." FDA, U.S. Department of Health and Human Services.

Abbreviations are sourced from "CLSI M100™, Performance Standards for Antimicrobial Susceptibility Testing, 36th ed. Clinical and Laboratory Standards Institute, 2026" and are commonly used by various manufacturers.

Notes

1. Market status reflects U.S. availability at time of publication (Oct 2026).
2. Trade names are included for reference and may change.
3. Some antimicrobials are retained for AST, educational, or international reference even when not currently marketed in the U.S.
4. AST abbreviations from CLSI M100 (current edition).
5. This guide is not intended to replace official prescribing information or FDA/CLSI guidance.
6. Not all antibiotics listed are on MicroScan panels.

To learn more about Beckman Coulter's microbiology solutions, scan the QR code.

BECKMAN COULTER

© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned hereinare trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. All other trademarks are the property of their respective owners.

MAPSS-3626-US-EN-v1

danaher